Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Immix Biopharma, Inc. (IMMX) had Normalized Pre-Tax Income of $-10.09M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-10.09M |
|
-- |
|
-- |
|
$10.80M |
|
$-10.80M |
|
$0.72M |
|
$-10.09M |
|
|
Normalized Pre-Tax Income |
$-10.09M |
$-10.09M |
|
$-10.09M |
|
$-10.09M |
|
$-10.09M |
|
$-10.80M |
|
$-10.67M |
|
55.37M |
|
55.37M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$92.27M |
|
$2.43M |
|
$3.54M |
|
$95.82M |
|
$10.54M |
|
-- |
|
$0.91M |
|
$11.45M |
|
$84.36M |
|
$84.36M |
|
$84.36M |
|
53.01M |
|
| Cash Flow Statement Financials | |
$-9.83M |
|
$-4.80M |
|
$-0.04M |
|
$93.93M |
|
$79.25M |
|
$-14.68M |
|
$0.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.76 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.86M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.96% |
|
-11.96% |
|
-10.53% |
|
-11.96% |
|
$1.59 |
|
$-0.18 |
|
$-0.18 |
|